Salahaden R Sultan1,2, Saoirse E O'Sullivan1, Timothy J England1. 1. Vascular Medicine, Division of Medical Sciences & Graduate Entry Medicine, School of Medicine, University of Nottingham, Royal Derby Hospital, Derby, UK. 2. Diagnostic Radiology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.
Abstract
BACKGROUND: In vivo studies show that cannabidiol (CBD) acutely reduces blood pressure (BP) in men. The aim of this study was to assess the effects of repeated CBD dosing on haemodynamics. METHODS: Twenty-six healthy males were given CBD (600 mg) or placebo orally for seven days in a randomised, placebo-controlled, double-blind, parallel study (n = 13/group). Cardiovascular parameters were assessed at rest and in response to isometric exercise after acute and repeated dosing using Finometer®, Vicorder® and Duplex ultrasound. RESULTS: Compared to placebo, CBD significantly reduced resting mean arterial pressure (P = .04, two-way ANOVA, mean difference (MD) -2 mmHg, 95% CI -3.6 to -0.3) after acute dosing, but not after repeated dosing. In response to stress, volunteers who had taken CBD had lower systolic BP after acute (P = .001, two-way ANOVA, MD -6 mmHg, 95% CI -10 to -1) and repeated (P = .02, two-way ANOVA, MD -5.7 mmHg, 95% CI -10 to -1) dosing. Seven days of CBD increased internal carotid artery diameter (MD +0.55 mm, P = .01). Within the CBD group, repeated dosing reduced arterial stiffness by day 7 (pulse wave velocity; MD -0.44 m/s, P = .05) and improved endothelial function (flow mediation dilatation, MD +3.5%, P = .02, n = 6 per group), compared to day 1. CONCLUSION: CBD reduces BP at rest after a single dose but the effect is lost after seven days of treatment (tolerance); however, BP reduction during stress persists. The reduction in arterial stiffness and improvements in endothelial function after repeated CBD dosing are findings that warrant further investigation in populations with vascular diseases.
BACKGROUND: In vivo studies show that cannabidiol (CBD) acutely reduces blood pressure (BP) in men. The aim of this study was to assess the effects of repeated CBD dosing on haemodynamics. METHODS: Twenty-six healthy males were given CBD (600 mg) or placebo orally for seven days in a randomised, placebo-controlled, double-blind, parallel study (n = 13/group). Cardiovascular parameters were assessed at rest and in response to isometric exercise after acute and repeated dosing using Finometer®, Vicorder® and Duplex ultrasound. RESULTS: Compared to placebo, CBD significantly reduced resting mean arterial pressure (P = .04, two-way ANOVA, mean difference (MD) -2 mmHg, 95% CI -3.6 to -0.3) after acute dosing, but not after repeated dosing. In response to stress, volunteers who had taken CBD had lower systolic BP after acute (P = .001, two-way ANOVA, MD -6 mmHg, 95% CI -10 to -1) and repeated (P = .02, two-way ANOVA, MD -5.7 mmHg, 95% CI -10 to -1) dosing. Seven days of CBD increased internal carotid artery diameter (MD +0.55 mm, P = .01). Within the CBD group, repeated dosing reduced arterial stiffness by day 7 (pulse wave velocity; MD -0.44 m/s, P = .05) and improved endothelial function (flow mediation dilatation, MD +3.5%, P = .02, n = 6 per group), compared to day 1. CONCLUSION: CBD reduces BP at rest after a single dose but the effect is lost after seven days of treatment (tolerance); however, BP reduction during stress persists. The reduction in arterial stiffness and improvements in endothelial function after repeated CBD dosing are findings that warrant further investigation in populations with vascular diseases.
Authors: Orrin Devinsky; Eric Marsh; Daniel Friedman; Elizabeth Thiele; Linda Laux; Joseph Sullivan; Ian Miller; Robert Flamini; Angus Wilfong; Francis Filloux; Matthew Wong; Nicole Tilton; Patricia Bruno; Judith Bluvstein; Julie Hedlund; Rebecca Kamens; Jane Maclean; Srishti Nangia; Nilika Shah Singhal; Carey A Wilson; Anup Patel; Maria Roberta Cilio Journal: Lancet Neurol Date: 2015-12-24 Impact factor: 44.182
Authors: José Alexandre S Crippa; Guilherme Nogueira Derenusson; Thiago Borduqui Ferrari; Lauro Wichert-Ana; Fábio L S Duran; Rocio Martin-Santos; Marcus Vinícius Simões; Sagnik Bhattacharyya; Paolo Fusar-Poli; Zerrin Atakan; Alaor Santos Filho; Maria Cecília Freitas-Ferrari; Philip K McGuire; Antonio Waldo Zuardi; Geraldo F Busatto; Jaime Eduardo Cecílio Hallak Journal: J Psychopharmacol Date: 2010-09-09 Impact factor: 4.153
Authors: Ellen W Leen-Feldner; Teah-Marie Bynion; Graham M L Eglit; Marcel O Bonn-Miller; L Riley Gournay; Matthew T Feldner Journal: Psychopharmacology (Berl) Date: 2022-10-15 Impact factor: 4.415
Authors: Natasha N Bondareva Williams; Taylor Russell Ewell; Kieran Shay Struebin Abbotts; Kole Jerel Harms; Keith A Woelfel; Gregory P Dooley; Tiffany L Weir; Christopher Bell Journal: Pharmaceuticals (Basel) Date: 2021-01-06
Authors: Olga Sadowska; Marta Baranowska-Kuczko; Anna Gromotowicz-Popławska; Michał Biernacki; Aleksandra Kicman; Barbara Malinowska; Irena Kasacka; Anna Krzyżewska; Hanna Kozłowska Journal: Int J Mol Sci Date: 2020-09-25 Impact factor: 5.923